KfW, Germany’s Development Bank, to implement partnership, ensuring continuity in funding for early-stage antimicrobial resistance research and late-stage clinical development. Lyon, 7 April 2026 – … The European Commission invests in CARB-X and GARDP to ramp up global response to antimicrobial resistance
Geneva/Labège, 23 March 2026 — The French biotech company Antabio and the GARDP Foundation (known as GARDP) today announced a joint effort to accelerate crucial … Antabio and GARDP join forces to identify potential next-generation antibiotics
Français German Geneva and Lausanne, Switzerland, 13 January 2026 – The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced … GARDP and Debiopharm partner to advance development of novel gonorrhoea drug
Français Geneva and Lausanne, Switzerland, 14 January 2025 – The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have … GARDP backs Debiopharm’s Swiss-developed compound to treat drug-resistant gonorrhoea infections
Seoul, 18 October 2024 – The Republic of Korea’s National Institute of Infectious Diseases (NIID) and the Global Antibiotic Research & Development Partnership (GARDP) have … The Republic of Korea’s National Institute of Infectious Diseases and GARDP team up to advance innovative clinical research on drug resistance
Geneva and Bangalore, 11 June 2024 – The Global Antibiotic Research & Development Partnership (GARDP) and Bugworks Research Inc. (Bugworks) today announced a collaboration agreement to co-develop … Novel broad-spectrum antibiotic compound prioritized for development in fight against AMR
Geneva, 29 May 2024 – The Global Antibiotic Research & Development Partnership (GARDP) and the Stop TB Partnership’s Global Drug Facility (GDF), hosted by UNOPS, … New partnership to improve access to new antibiotics in low- and middle-income countries to boost efforts to combat TB and AMR
Geneva, 21 February 2024 – The Global Antibiotic Research & Development Partnership (GARDP) announced today an additional investment of £2.5 million from the UK Government. The … UK Government pledges £2.5 million towards new antibiotic treatments
Geneva, Switzerland, 20 November 2023 – In a boost to efforts to counter antibiotic resistance, the Research Investment for Global Health Technology (RIGHT) Foundation has … The RIGHT Foundation invests in new treatments for neonatal sepsis
A phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current … Positive results announced in largest pivotal phase 3 trial of a first-in-class oral antibiotic to treat uncomplicated gonorrhoea